← Back to Search

Monoclonal Antibodies

Avelumab for Solid Tumors

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
BRCA1, BRCA2 and/or ATM gene defect.
Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to approximately 24 months
Awards & highlights

Study Summary

This trial will investigate if avelumab in combination with talazoparib can treat patients with locally advanced or metastatic solid tumors that have a BRCA or ATM defect.

Eligible Conditions
  • Solid Tumors
  • BRCA1 (Breast Cancer 1)

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to approximately 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to approximately 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Confirmed Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Secondary outcome measures
DoR as Assessed by Investigator
Duration of Response (DoR) as Assessed by BICR
Number of Participants With Cancer Antigen 125 (CA-125) Response
+21 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Combination of avelumab and talazoparibExperimental Treatment2 Interventions
Single arm open label
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Avelumab
2018
Completed Phase 2
~2450
Talazoparib
2021
Completed Phase 2
~2740

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,556 Previous Clinical Trials
10,907,250 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,467 Previous Clinical Trials
8,088,725 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What has been revealed regarding the security of Avelumab for patients?

"Our in-house analysis has rated the safety of avelumab at a 2, as it is currently undergoing Phase 2 trials and there are some encouraging signs regarding its safety profile but insufficient data to prove efficacy."

Answered by AI

How many subjects are receiving treatments as part of this clinical trial?

"Unfortunately, this experiment has concluded its recruitment process. Initially posted on June 18th 2018 and last updated September 26h 2022, so no further patients are sought after at present. There are 17 trials seeking individuals with brca 1 genes and 161 studies recruiting for Avelumab treatment respectively."

Answered by AI

How many medical facilities are conducting this research project?

"This medical experiment is welcoming participants from 61 different locations, including Northside Hospital-GCS/Macon in Macon, Georgia; The Sarah Cannon Research Institute in Hermitage, Massachusetts; and Brigham and Women's Hospital in Boston, Ohio."

Answered by AI

What therapeutic purposes does Avelumab tend to be employed for?

"Avelumab is a viable treatment option for conditions such as advance directives, BRCA1 gene mutations and Merkel cell carcinoma."

Answered by AI

Are there still openings available in this research study?

"Unfortunately, per clinicaltrials.gov this study is not currently recruiting patients. It was initially announced on June 18th, 2018 and has been updated most recently on September 26th 2022. Nevertheless, 178 other medical studies are actively seeking participants at the moment."

Answered by AI

Are there any published reports about the effectiveness of Avelumab in clinical trials?

"Avelumab was first investigated by City of Hope in 2010, and since then 70 clinical trials have been finished. Currently, 161 more are ongoing with many being conducted out of Macon, Georgia."

Answered by AI
~30 spots leftby Mar 2025